An interventional study of transcutaneous auricular vagus nerve stimulation (taVNS) and traditional medical treatment for PHN in Post Herpetic Neuralgia (PHN), sponsored by Mohamed Hosny Ismail Easa. Completed at 1 site in Egypt. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Mohamed Hosny Ismail Easa · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Neuralgia, Postherpetic with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Neuralgia, Postherpetic · Egypt.
Among the 10 studies in Neuralgia, Postherpetic with a site in Egypt, this one is the 10th largest by enrollment, is one of 5 that started in 2025, is one of 9 with no phase, and was the 6th registered.
197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.
Browse Neuralgia, Postherpetic studies →4 of the 10 studies in Neuralgia, Postherpetic with a site in Egypt are open now. Recruiting first, the newest first:
Alexandria University · Sites in Egypt
Ages 20–70
Cairo University · Sites in Egypt
Ages 18–75
Zagazig University · Sites in Egypt
Ages 18+
Sohag University · Sites in Egypt
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 35 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 5 started in 2025.
This study's enrollment of 34 is below the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.
Median enrollment 56 across the 10 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 8 most frequent:
This is the only study on the registry with Mohamed Hosny Ismail Easa as lead sponsor.
Mohamed Hosny Ismail Easa has 1 study filed under Neuralgia, Postherpetic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Neuralgia, Postherpetic with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN). Participants will receive taVNS in addition to standard care. The study aims to determine whether taVNS can provide significant pain relief and improve quality of life in PHN patients.
Post-herpetic neuralgia (PHN) is a chronic neuropathic pain condition that persists for months or years following the resolution of herpes zoster (HZ) infection. It is characterized by persistent burning, stabbing, or shooting pain, often accompanied by allodynia and hyperalgesia, which can significantly impair quality of life. Current treatment options for PHN, including pharmacological therapies, often provide incomplete pain relief and are associated with side effects, creating a need for novel, non-invasive interventions.
This randomized controlled trial aims to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) as an adjunct to standard medical treatment for patients with PHN. The vagus nerve plays a crucial role in modulating pain perception and inflammatory processes, and its non-invasive stimulation through the auricular branch has shown promising analgesic effects in various chronic pain syndromes.
A total of 34 male and female participants, aged 35-65 years, diagnosed with PHN will be randomly allocated into two equal groups (17 participants per group). Group A (Experimental) will receive taVNS in addition to conventional pharmacological management, while Group B (Control) will receive conventional pharmacological management alone. The taVNS intervention will be delivered using the EV-906 device with TENS ear clips, applied according to the study protocol and safety standards (ISO 13485, FDA QSR, and CE compliance).
Pain intensity and quality will be assessed at baseline, after two weeks, and after four weeks using validated outcome measures: the Brief Pain Inventory (BPI) short form and the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2). The primary outcome is the change in pain severity scores, and the secondary outcome is the change in pain interference with daily activities.
The results of this study will provide evidence regarding the clinical utility of taVNS as a safe, non-invasive, and effective adjunct therapy for PHN, with the potential to improve patient outcomes and quality of life
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 35-65 years diagnosed with PHN. Persistent pain for at least 3 months after herpes zoster infection. Only patients who sign the form will be included.
Exclusion Criteria:
to taVNS such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
this group will receive taVNS in addition to traditional medical treatment
Device: transcutaneous auricular vagus nerve stimulation (taVNS)
this group will receive the same traditional medical treatment only
Other: traditional medical treatment for PHN
Use of the EV-906 device with TENS ear clips for transcutaneous auricular vagus nerve stimulation (taVNS), applied according to the study protocol, in addition to standard medical treatment for post-herpetic neuralgia. This device meets ISO 13485, FDA QSR, and CE standards
Standard medical treatment for post-herpetic neuralgia as per current clinical guidelines, without the application of taVNS device.
Brief Pain Inventory-Short Form (BPI-SF) Total Score
the Brief Pain Inventory-Short Form (BPI SF) is a valuable tool for assessing pain severity and its impact on daily functioning on a 0-10 numeric rating scale, with higher scores indicating more severe pain.
Time frame: Baseline, 2 weeks, and 4 weeks
Short Form McGill Pain Questionnaire 2 (SF-MPQ-2)
The SF-MPQ-2 is a validated tool assessing sensory, affective, and evaluative qualities of pain. Participants rate the intensity of their pain using a 0-10 scale: 0: No pain 10: Worst pain imaginable Participants select the rating that best reflects their experience during the past week.
Time frame: Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based.
Thirty-four (34) patients diagnosed with post-herpetic neuralgia (PHN) were recruited for this study. Participants were aged between 35 and 65 years and included both sexes. They were recruited from the Pain Clinic of Zagazig University Hospitals. Eligible participants were randomly assigned into two equal groups (n = 17 per group).
| Milestone | Group (A): Study Group | Group (B): Control Group |
|---|---|---|
| Started | 17 | 17 |
| Completed | 17 | 17 |
| Not completed | 0 | 0 |
the Brief Pain Inventory-Short Form (BPI SF) is a valuable tool for assessing pain severity and its impact on daily functioning on a 0-10 numeric rating scale, with higher scores indicating more severe pain.
| points | Group (A): Study Group | Group (B): Control Group |
|---|---|---|
| baseline scores | 6.73 ± 1.11 | 6.29 ± 1.22 |
| after 2 weeks scores | 4.52 ± 1.12 | 4.88 ± 1.30 |
| after 4 weeks scores | 2.95 ± 1.16 | 3.92 ± 1.69 |
The SF-MPQ-2 is a validated tool assessing sensory, affective, and evaluative qualities of pain. Participants rate the intensity of their pain using a 0-10 scale: 0: No pain 10: Worst pain imaginable Participants select the rating that best reflects their experience during the past week.
| score | Group (A): Study Group | Group (B): Control Group |
|---|---|---|
| baseline scores | 6.73 ± 1.11 | 6.29 ± 1.22 |
| after 2 weeks scores | 4.52 ± 1.12 | 4.88 ± 1.30 |
| after 4 weeks scores | 2.95 ± 1.16 | 3.92 ± 1.69 |
Collected over From enrollment until 4 weeks after treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group (A): Study Group | 0/17 (0%) | 0/17 (0%) | 0/17 (0%) |
| Group (B): Control Group | 0/17 (0%) | 0/17 (0%) | 0/17 (0%) |
All randomized participants were included in the baseline analysis
| Age, Customized(years) | Group (A): Study Group | Group (B): Control Group | Total |
|---|---|---|---|
| age Baseline Characteristics | 53.5 ± 6.7 | 55.4 ± 5.3 | 54.45 ± 6.03 |
| Sex: Female, Male(Participants) | Group (A): Study Group | Group (B): Control Group | Total |
|---|---|---|---|
| Female | 5 | 9 | 14 |
| Male | 12 | 8 | 20 |
| Race and Ethnicity Not Collected(Participants) | Group (A): Study Group | Group (B): Control Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Brief Pain Inventory short form total score at baseline(points) | Group (A): Study Group | Group (B): Control Group | Total |
|---|---|---|---|
| Mean | 6.73 ± 1.11 | 6.29 ± 1.22 | 6.51 ± 1.16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data will not be shared due to participant confidentiality and restrictions imposed by the institutional ethics committee
Ran from Sep 2025 to primary completion in Sep 2026, 12 months.
Results were first posted in Oct 2026, 1 month after primary completion.
Of 30 non-industry interventional studies with no phase under Neuralgia, Postherpetic, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 12 months is below that.
Counting every sponsor, half of 32 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.